Should Value Investors Buy Genpact (G) Stock?

23.12.24 15:40 Uhr

Werte in diesem Artikel
Aktien

40,82 EUR -0,20 EUR -0,49%

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.One company value investors might notice is Genpact (G). G is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. The stock is trading with a P/E ratio of 12.30, which compares to its industry's average of 25.42. Over the past year, G's Forward P/E has been as high as 13.92 and as low as 9.75, with a median of 11.15.Investors will also notice that G has a PEG ratio of 1.25. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. G's PEG compares to its industry's average PEG of 2.69. Over the last 12 months, G's PEG has been as high as 1.66 and as low as 1.23, with a median of 1.36.Finally, we should also recognize that G has a P/CF ratio of 9.97. This metric focuses on a firm's operating cash flow and is often used to find stocks that are undervalued based on the strength of their cash outlook. G's current P/CF looks attractive when compared to its industry's average P/CF of 17.07. Within the past 12 months, G's P/CF has been as high as 11.84 and as low as 7.46, with a median of 8.68.These figures are just a handful of the metrics value investors tend to look at, but they help show that Genpact is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, G feels like a great value stock at the moment.Zacks Naming Top 10 Stocks for 2025Want to be tipped off early to our 10 top picks for the entirety of 2025?History suggests their performance could be sensational.From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2025. Don’t miss your chance to get in on these stocks when they’re released on January 2.Be First to New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Genpact Limited (G): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Genpact

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Genpact

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Genpact LtdShs

Analysen zu Genpact LtdShs

DatumRatingAnalyst
08.08.2019Genpact BuyNeedham & Company, LLC
14.06.2019Genpact BuyNeedham & Company, LLC
04.08.2017Genpact Market PerformBMO Capital Markets
04.08.2017Genpact NeutralWedbush Morgan Securities Inc.
11.04.2016Genpact UnderperformRBC Capital Markets
DatumRatingAnalyst
08.08.2019Genpact BuyNeedham & Company, LLC
14.06.2019Genpact BuyNeedham & Company, LLC
04.08.2017Genpact Market PerformBMO Capital Markets
29.08.2011Genpact outperformOppenheimer & Co. Inc.
19.05.2011Genpact outperformOppenheimer & Co. Inc.
DatumRatingAnalyst
04.08.2017Genpact NeutralWedbush Morgan Securities Inc.
02.03.2015Genpact HoldDeutsche Bank AG
05.02.2015Genpact HoldDeutsche Bank AG
DatumRatingAnalyst
11.04.2016Genpact UnderperformRBC Capital Markets
30.07.2010Genpact sellKaufman Bros., LP

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Genpact LtdShs nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"